Impact of HLA-A2 Status on Ipilimumab Efficacy and Safety: Pooled Data from Four Phase II Trials in Advanced Melanoma
2010-01-01 Wolchok, Jd; Weber, Js; Hamid, O; Lebbe, C; Maio, M; Schadendorf, D; de Pril, V; Ibrahim, R; Hoos, A; O'Day, Sj
Immunomodulatory activity of SGI-110, a 5-aza-2 '-deoxycytidine-containing demethylating dinucleotide
2010-01-01 Coral, S; Sigalotti, L; Parisi, G; Colizzi, F; Fratta, E; Nicolay, Hjm; Taverna, P; Maio, M
Health-Care resource Utilization in advanced melanoma: an analysis from the MELODY observational study
2010-01-01 Lorigan, P; Maio, M; Middleton, M; Testori, A; Bedane, C; van Baardewijk, M; Konto, C; Dueymes, A; Lebbe, C
Immunobiologic Activity of the Demethylating Dinucleotide SGI-110
2010-01-01 Coral, S; Sigalotti, L; Fonsatti, E; Parisi, G; Colizzi, F; Nicolay, Hj; Taverna, P; Maio, M
Clinical Efficacy of the Anti-Cytotoxic T Lymphocyte Antigen-4 (CTLA-4) Monoclonal Antibody Ipilimumab in Pretreated Metastatic Uveal Melanoma Patients
2010-01-01 Danielli, R; Queirolo, P; Testori, A; Plummer, R; Sileni Chiarion, V; Altomonte, M; Calabro, L; DI GIACOMO, ANNA MARIA; Ridolfi, R; Maio, M
Specific cellular immune responses against NY-ESO-1 are associated with favorable survival of stage IV melanoma patients
2011-01-01 Weide, B; Zelba, H; Derhovanessian, E; Pflugfelder, A; Schadendorf, D; de Vries, J; Maio, M; Garbe, C; Pawelec, G
A Phase II Study Combining Ipilimumab and Fotemustine in Patients With Metastatic Melanoma - the NIBIT-M1 Trial
2011-01-01 DI GIACOMO, ANNA MARIA; Ascierto, Pa; Pittiglio, E; Queirolo, P; Pilla, L; Ridolfi, R; Santinami, M; Testori, A; Parmiani, G; Maio, M
Phase 3 Randomized Study of Ipilimumab (IPI) Plus Dacarbazine (DTIC) Vs DTIC Alone as First Line Treatment in Patients With Unresectable Stage III or IV Melanoma
2011-01-01 Robert, C; Thomas, L; Garbe, C; Lebbe, C; Baurain, Jf; Testori, A; Maio, M; Chen, T; Hoos, A; Wolchok, J
Estratto della tesi di dottorato: “Il principio del vivente nelle anonime Questiones super librum de anima (ms. Siena, Bibl. Com. degli Intronati L.III.21, ff. 136ra-174ra”,
2005-01-01 Bernardini, Paola
Guest Editorial “Secure lightweight crypto-hardware”
2017-01-01 Acosta, A.; Addabbo, T.
Comparative Serum Protein Profiles in IPF Patients Before and After Nintedanib Therapy
2019-01-01 Bargagli, E; Bergantini, L; Cameli, P; D'Alessandro, M; Bini, L; Rottoli, P; Landi, C
Efficacy and safety of ipilimumab in patients with pretreated, ocular melanoma: experience from Italian clinics participating in the European expanded access programme (EAP)
2012-01-01 Maio, M; Chiarion Sileni, V; Pilla, L; Nicoletti, Svl; Di Guardo, L; Queirolo, P; De Galitiis, F; Mandala, M; Guida, M; Ascierto, Pa
The NIBIT-M1 trial: Activity of ipilimumab plus fotemustine in patients with melanoma and brain metastases
2012-01-01 Maio, M; Testori, A; Ascierto, Pa; Ridolfi, R; Santinami, M; Pilla, L; Queirolo, P; Grosso, M; Simeone, E; Vittoria, S; Nicoletti, L; Rivoltini, L; Ferrucci, Pf; Parmiani, G; DI GIACOMO, ANNA MARIA
Prognostic Potential of Integrated Whole Genome Methylation and Expression Profiling in Cutaneous Melanoma
2012-01-01 Sigalotti, L; Fratta, E; Parisi, G; Covre, A; Sonego, P; Rizzo, A; Colizzi, F; Coral, S; Massarut, S; Maio, M
Economic impact of healthcare resource utilisation patterns among patients diagnosed with advanced melanoma in the United Kingdom, Italy, and France: Results from a retrospective, longitudinal survey (MELODY study)
2011-01-01 Johnston, K; Levy, Ar; Lorigan, P; Maio, M; Lebbé, C; Middleton, M; Testori, A; Bédane, C; Konto, C; Dueymes, A; van Baardewijk, M
Morphological and functional characterization of IL12 Receptor beta2 chain on intestinal epithelial cells: implications for local and systemic immunoregulation
2018-01-01 Nicoletti, C.; Regoli, M.; Pacini, A.; Branca, J. J. V.; Man, A. L.; Morucii, G.; Narbad, A.; Gulisano, M.; Bertelli, E.
Guidelines Versus Measurements in Real Setting: Modelling Microbial Airborne Contamination and Air Flow in Operating Theaters
2018-01-01 Vonci, Niccolò; Spataro, Giuseppe; De Marco, Maria Francesca; Nante, Nicola; Cevenini, Gabriele; Messina, Gabriele
Survival analysis with 5 years of follow-up in a phase III study of ipilimumab and dacarbazine in metastatic melanoma
2013-01-01 Maio, M; Bondarenko, I; Robert, C; Thomas, L; Garbe, C; Testori, A; Lu, H; Chin, K; Wolchok, J
Five-year survival rates for patients (pts) with metastatic melanoma (mm) treated with ipilimumab (ipi) in phase II trials
2012-01-01 Lebbe, C; Weber, Js; Maio, M; Neyns, B; Harmankaya, K; Chin, K; Mcdowell, Do; Cykowski, L; Mchenry, Mb; Wolchok, Jd
Expression of p34(cdc2) and cyclin B-1 in Hodgkin's disease and anaplastic large cell lymphomas
1997-01-01 Leoncini, L.; Megha, T.; Lazzi, S.; Bellan, C.; Vatti, R.; Luzi, P.; Tosi, P.; Pileri, S.; Cottier, H.
| Titolo | Data di pubblicazione | Autore(i) | File | Abstract |
|---|---|---|---|---|
| Impact of HLA-A2 Status on Ipilimumab Efficacy and Safety: Pooled Data from Four Phase II Trials in Advanced Melanoma | 1-gen-2010 | Wolchok, Jd; Weber, Js; Hamid, O; Lebbe, C; Maio, M; Schadendorf, D; de Pril, V; Ibrahim, R; Hoos, A; O'Day, Sj | - | |
| Immunomodulatory activity of SGI-110, a 5-aza-2 '-deoxycytidine-containing demethylating dinucleotide | 1-gen-2010 | Coral, S; Sigalotti, L; Parisi, G; Colizzi, F; Fratta, E; Nicolay, Hjm; Taverna, P; Maio, M | - | |
| Health-Care resource Utilization in advanced melanoma: an analysis from the MELODY observational study | 1-gen-2010 | Lorigan, P; Maio, M; Middleton, M; Testori, A; Bedane, C; van Baardewijk, M; Konto, C; Dueymes, A; Lebbe, C | - | |
| Immunobiologic Activity of the Demethylating Dinucleotide SGI-110 | 1-gen-2010 | Coral, S; Sigalotti, L; Fonsatti, E; Parisi, G; Colizzi, F; Nicolay, Hj; Taverna, P; Maio, M | - | |
| Clinical Efficacy of the Anti-Cytotoxic T Lymphocyte Antigen-4 (CTLA-4) Monoclonal Antibody Ipilimumab in Pretreated Metastatic Uveal Melanoma Patients | 1-gen-2010 | Danielli, R; Queirolo, P; Testori, A; Plummer, R; Sileni Chiarion, V; Altomonte, M; Calabro, L; DI GIACOMO, ANNA MARIA; Ridolfi, R; Maio, M | - | |
| Specific cellular immune responses against NY-ESO-1 are associated with favorable survival of stage IV melanoma patients | 1-gen-2011 | Weide, B; Zelba, H; Derhovanessian, E; Pflugfelder, A; Schadendorf, D; de Vries, J; Maio, M; Garbe, C; Pawelec, G | - | |
| A Phase II Study Combining Ipilimumab and Fotemustine in Patients With Metastatic Melanoma - the NIBIT-M1 Trial | 1-gen-2011 | DI GIACOMO, ANNA MARIA; Ascierto, Pa; Pittiglio, E; Queirolo, P; Pilla, L; Ridolfi, R; Santinami, M; Testori, A; Parmiani, G; Maio, M | - | |
| Phase 3 Randomized Study of Ipilimumab (IPI) Plus Dacarbazine (DTIC) Vs DTIC Alone as First Line Treatment in Patients With Unresectable Stage III or IV Melanoma | 1-gen-2011 | Robert, C; Thomas, L; Garbe, C; Lebbe, C; Baurain, Jf; Testori, A; Maio, M; Chen, T; Hoos, A; Wolchok, J | - | |
| Estratto della tesi di dottorato: “Il principio del vivente nelle anonime Questiones super librum de anima (ms. Siena, Bibl. Com. degli Intronati L.III.21, ff. 136ra-174ra”, | 1-gen-2005 | Bernardini, Paola | - | |
| Guest Editorial “Secure lightweight crypto-hardware” | 1-gen-2017 | Acosta, A.; Addabbo, T. | - | |
| Comparative Serum Protein Profiles in IPF Patients Before and After Nintedanib Therapy | 1-gen-2019 | Bargagli, E; Bergantini, L; Cameli, P; D'Alessandro, M; Bini, L; Rottoli, P; Landi, C | - | |
| Efficacy and safety of ipilimumab in patients with pretreated, ocular melanoma: experience from Italian clinics participating in the European expanded access programme (EAP) | 1-gen-2012 | Maio, M; Chiarion Sileni, V; Pilla, L; Nicoletti, Svl; Di Guardo, L; Queirolo, P; De Galitiis, F; Mandala, M; Guida, M; Ascierto, Pa | - | |
| The NIBIT-M1 trial: Activity of ipilimumab plus fotemustine in patients with melanoma and brain metastases | 1-gen-2012 | Maio, M; Testori, A; Ascierto, Pa; Ridolfi, R; Santinami, M; Pilla, L; Queirolo, P; Grosso, M; Simeone, E; Vittoria, S; Nicoletti, L; Rivoltini, L; Ferrucci, Pf; Parmiani, G; DI GIACOMO, ANNA MARIA | - | |
| Prognostic Potential of Integrated Whole Genome Methylation and Expression Profiling in Cutaneous Melanoma | 1-gen-2012 | Sigalotti, L; Fratta, E; Parisi, G; Covre, A; Sonego, P; Rizzo, A; Colizzi, F; Coral, S; Massarut, S; Maio, M | - | |
| Economic impact of healthcare resource utilisation patterns among patients diagnosed with advanced melanoma in the United Kingdom, Italy, and France: Results from a retrospective, longitudinal survey (MELODY study) | 1-gen-2011 | Johnston, K; Levy, Ar; Lorigan, P; Maio, M; Lebbé, C; Middleton, M; Testori, A; Bédane, C; Konto, C; Dueymes, A; van Baardewijk, M | - | |
| Morphological and functional characterization of IL12 Receptor beta2 chain on intestinal epithelial cells: implications for local and systemic immunoregulation | 1-gen-2018 | Nicoletti, C.; Regoli, M.; Pacini, A.; Branca, J. J. V.; Man, A. L.; Morucii, G.; Narbad, A.; Gulisano, M.; Bertelli, E. | - | |
| Guidelines Versus Measurements in Real Setting: Modelling Microbial Airborne Contamination and Air Flow in Operating Theaters | 1-gen-2018 | Vonci, Niccolò; Spataro, Giuseppe; De Marco, Maria Francesca; Nante, Nicola; Cevenini, Gabriele; Messina, Gabriele | - | |
| Survival analysis with 5 years of follow-up in a phase III study of ipilimumab and dacarbazine in metastatic melanoma | 1-gen-2013 | Maio, M; Bondarenko, I; Robert, C; Thomas, L; Garbe, C; Testori, A; Lu, H; Chin, K; Wolchok, J | - | |
| Five-year survival rates for patients (pts) with metastatic melanoma (mm) treated with ipilimumab (ipi) in phase II trials | 1-gen-2012 | Lebbe, C; Weber, Js; Maio, M; Neyns, B; Harmankaya, K; Chin, K; Mcdowell, Do; Cykowski, L; Mchenry, Mb; Wolchok, Jd | - | |
| Expression of p34(cdc2) and cyclin B-1 in Hodgkin's disease and anaplastic large cell lymphomas | 1-gen-1997 | Leoncini, L.; Megha, T.; Lazzi, S.; Bellan, C.; Vatti, R.; Luzi, P.; Tosi, P.; Pileri, S.; Cottier, H. | - |
Legenda icone
- file ad accesso aperto
- file disponibili sulla rete interna
- file disponibili agli utenti autorizzati
- file disponibili solo agli amministratori
- file sotto embargo
- nessun file disponibile
Scopri
Tipologia
- 1 Contributo su Rivista1865
Data di pubblicazione
- 2020 - 2025162
- 2010 - 2019719
- 2000 - 2009721
- 1990 - 1999226
- 1980 - 198934
- 1974 - 19793
Editore
- Elsevier1
- Eular Publishers:Missionsstrasse 36, CH-4012 Basel Switzerland:011 41 61 2646470, EMAIL: [email protected], Fax: 011 41 61 26464881
- F K Schattauer Verlagsgesellschaft mbH:Postfach 104545, D-70040 Stuttgart Germany:011 49 711 2298726, EMAIL: [email protected], INTERNET: http://www.schattauer.de, Fax: 011 49 711 22987501
- Firenze University Press1
- Fondaz Ferrata Storti:Strada Nuova 134, 27100 Pavia Italy:011 39 0382 531182, EMAIL: [email protected], Fax: 011 39 0382 277211
- JOHN WILEY & SONS LTD1
Rivista
- EUROPEAN JOURNAL OF PUBLIC HEALTH192
- MULTIPLE SCLEROSIS72
- URODINAMICA60
- EUROPEAN UROLOGY. SUPPLEMENTS39
- PEDIATRIC RESEARCH36
- ANNALS OF ONCOLOGY26
- THE JOURNAL OF UROLOGY26
- ACTA OPHTHALMOLOGICA24
- EUROPEAN RESPIRATORY JOURNAL23
- HELICOBACTER23
Keyword
- Hypoxia9
- Biomarkers8
- nonlinear analysis8
- Idiopathic pulmonary fibrosis7
- biomarkers6
- cirrhosis6
- thrombin6
- Caretta caretta5
- fractal analysis5
- botulinum a toxin4
Lingua
- eng1520
- ita130
- fre6
- und2
- ger1
- por1
- spa1
Accesso al fulltext
- no fulltext1291
- reserved464
- open93
- internalNetwork13
- partially open4
Appartenenza
- Dipartimento di Biotecnologie Mediche402
- Dipartimento di Biotecnologie, Chimica e Farmacia113
- Dipartimento di Filologia e Critica delle Letterature Antiche e Moderne5
- Dipartimento di Giurisprudenza2
- Dipartimento di Ingegneria dell'Informazione e Scienze Matematiche19
- Dipartimento di Medicina Molecolare e dello Sviluppo534
- Dipartimento di Scienze della Formazione, Scienze Umane e della Comunicazione Interculturale1
- Dipartimento di Scienze della Vita252
- Dipartimento di Scienze Fisiche, della Terra e dell'Ambiente103
- Dipartimento di Scienze Mediche, Chirurgiche e Neuroscienze879